Story
SpaceX Braces for ~$123 Billion Lockup Expiry in Early August 2026

Summary
SpaceX faces a significant liquidity event as a lockup agreement on approximately $123 billion worth of shares is set to expire following its first quarterly report, creating potential selling pressure on the stock.
SpaceX (SPCX) is confronting a massive potential supply shock as shares worth an estimated $123 billion are scheduled to be unlocked in early August 2026. This event poses a significant test for the aerospace company's stock, which has already traded below its $135 IPO price ahead of the expiry.
The Unlocking Mechanism
The lockup expiry is tied to the company's debut quarterly earnings report, expected in early August. Two days after the report is released, a major tranche of shares held by employees and early investors will become eligible for sale on the public market.
Investors are monitoring two distinct tranches:
- Unconditional Lockup: Approximately 911.5 million shares, valued at around $123 billion at current prices, will unlock regardless of the stock's performance.
- Price-Contingent Lockup: A second tranche of 455.8 million shares, valued at roughly $62 billion, will only unlock if the stock trades at or above $175.50 for five out of ten consecutive trading days leading up to the earnings release. As of July 15, the stock closed at $135.27, well below this trigger.
Market Impact and Scale
AdThe scale of the impending share release is substantial. The $123 billion unconditional tranche is approximately 68 times larger than the typical $1.8 billion lockup expiry for a large-cap company and is 64% larger than the $75 billion SpaceX raised in its record-setting IPO.
A lockup expiry allows insiders, who acquired shares pre-IPO at lower valuations, to sell their holdings for the first time. This can create significant selling pressure as they look to realize profits, potentially overwhelming buying demand and driving the stock price lower.
Investor Outlook
The situation presents a classic bull versus bear scenario. The bearish view points to the stock's weakness ahead of the expiry—a historically challenging sign for newly public companies. The sheer volume of shares becoming available could create a supply overhang that weighs on the stock for some time.
Conversely, bulls may argue that not all insiders will rush to sell, particularly long-term believers in the company's vision. Furthermore, a strong earnings report could serve as a positive catalyst, shifting the market narrative ahead of the unlock. According to Reuters data, even IPOs that fall below their offering price have historically shown a median subsequent gain of 61%, suggesting a recovery is possible.
Read next
More on Stocks
Telix Pharmaceuticals to Acquire ITM Isotope Technologies for $1.65 Billion
The Australian radiopharmaceutical firm will acquire the German isotope supplier in a deal aimed at vertically integrating its supply chain. The transaction includes $1.25 billion in stock and the assumption of debt.

Jefferies Forecasts S&P 500 to Reach 9,000 by End of 2027 on Earnings Strength
The investment bank set a 2026 year-end target of 8,000 for the index, citing stronger-than-expected corporate earnings and sustained investment in artificial intelligence as key drivers.

S&P 500 Historically Rallies After Midterm Elections, UBS Analysis Shows
U.S. stocks have historically posted strong gains in the months following midterm elections after a period of heightened volatility, according to a research note from UBS.

MOEX Russia Index Closes Flat as Energy Gains Offset Broader Market Declines
Russia's main stock index finished Sunday's session unchanged, as a rally in heavyweight energy stocks like Rosneft masked weakness across the broader market, where declining stocks outnumbered advancers.